Septerna, Inc.
Clinical-stage biotech developing oral small molecule medicines targeting GPCRs.
SEPN | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 250 EAST GRAND AVENUE, SUITE 65, 94080 SOUTH SAN FRANCISCO
- Website:
- https://septerna.com/
Description
Septerna, Inc. is a clinical-stage biotechnology company that discovers and develops novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs). The company leverages its proprietary Native Complex Platform™ to isolate and analyze GPCRs in their natural state, which facilitates the development of new therapies. Septerna is advancing a wholly-owned pipeline with an initial focus on endocrinology, immunology, inflammation, and metabolic diseases. One of its clinical programs involves SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator being evaluated for the treatment of mast cell-driven diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Septerna, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Septerna, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Septerna, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
